OakChart

Royalty Pharma plc

RPRXHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 10:37 AM ET

69.09-0.36 (-0.52%)
2026-11-11 16:37 CET
Market cap
30,923.72 USD m
Revenue, TTM
2,616.82 USD m
Net income, TTM
671.25 USD m
Free cash flow, TTM
2,994.99 USD m
EPS diluted, TTM
1.54
P/E
44.95
Compare

Price

RPRX against its 20, 50 and 200-day averages
2050200beatmiss
40.0050.0060.0070.009.0M17.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RPRXclose 69.0920-day 65.1750-day 61.27200-day 54.3469.09

1.1% under the 52-week high of 69.83 on 11 Nov 2026. 52-week low 37.31 on 24 Nov 2025. Last 15 sessions, 12.0% high to low

Profile

RPRX
52-week range, 98% of the way up
37.3169.77

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

IndexRUI
Employees100
IPOJun 16, 2020
Beta0.35
ATR, 14d1.55
Rel volume0.80
Short float3.13%
Insider own6.32%
Inst own86.90%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap39.63B
Enterprise Value50.63B
Income671.25M
Sales2.62B
Book/sh15.34
Cash/sh0.95
Dividend Est.1.03 (1.50%)
Dividend TTM0.92 (1.34%)
Dividend Ex-DateNov 13, 2026
Dividend Gr. 3/5Y5.01% 24.01%
Payout49.40%
Employees100
IPOJun 16, 2020

Ratios

P/E44.95
Forward P/E11.69
PEG1.07
P/S15.15
P/B4.51
P/C72.74
P/FCF13.23
EV/EBITDA29.44
EV/Sales19.35
Quick Ratio1.29
Current Ratio1.29
Debt/Eq1.26
LT Debt/Eq1.11
Option/ShortYes / Yes

Earnings

EPS (ttm)1.54
EPS next Y5.91
EPS next Q1.57
EPS this Y11.65%
EPS next Y9.61%
EPS next 5Y10.92%
EPS past 3/5Y163.11% -7.26%
Sales past 3/5Y2.06% 2.30%
EPS Y/Y TTM-12.26%
Sales Y/Y TTM11.34%
EPS Q/Q-51.34%
Sales Q/Q13.26%
EarningsNov 04 BMO
EPS/Sales Surpr.2.31% 0.58%

Ownership

Insider Own6.32%
Insider Trans-1.66%
Inst Own86.90%
Inst Trans2.09%
ROA3.46%
ROE10.13%
ROIC4.65%
Gross Margin99.81%
Oper. Margin65.53%
Profit Margin25.65%
SMA206.01%
SMA5012.76%
SMA20027.15%
Trades-

Technical

Shs Outstand445.82M
Shs Float417.14M
Short Float3.13%
Short Ratio4.19
Short Interest13.08M
52W High69.77 -0.97%
52W Low37.31 85.18%
Volatility3.22% 2.41%
ATR (14)1.55
RSI (14)75.01
Beta0.35
Rel Volume0.80
Avg Volume3.12M
Volume532,169

Performance

Perf Week2.26%
Perf Month22.13%
Perf Quarter17.98%
Perf Half Y29.75%
Perf YTD78.80%
Perf Year77.34%
Perf 3Y153.82%
Perf 5Y71.91%
Perf 10Y-
Recom1.50
Target Price72.71
Prev Close69.45
Price69.09
Change %-0.52%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 30, 2026UpgradeUUBSNeutral → Buy$49-29.1%
Sep 30, 2025InitiatedGGoldmanBuy$42-39.2%
May 16, 2025InitiatedMMorgan StanleyOverweight$51-26.2%
Jun 03, 2024DowngradeUUBSBuy → Neutral$28-59.5%
Jun 14, 2022ResumedUUBSBuy$47-32.0%
May 13, 2022InitiatedBScotiabankSector Outperform$53-23.3%
Apr 27, 2022InitiatedGGoldmanBuy$56-18.9%
Apr 14, 2022UpgradeJJP MorganNeutral → Overweight$50-27.6%
Apr 06, 2022ResumedMMorgan StanleyOverweight$48-30.5%
Oct 29, 2021UpgradeCCitigroupNeutral → Buy$50-27.6%

Peers

Mkt cap
TickerCompanyMkt cap
LGNDLigand Pharmaceuticals Inc6.37B
HALOHalozyme Therapeutics Inc11.47B
INVAInnoviva Inc1.33B
VRTXVertex Pharmaceuticals Inc136.63B
RVMDRevolution Medicines Inc40.04B
ALNYAlnylam Pharmaceuticals Inc20.78B
BIIBBiogen Inc37.12B
EXELExelixis Inc17.12B
GILDGilead Sciences Inc210.98B
AMGNAMGEN Inc250.16B

Insider trading

latest 14 of 82
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Urist MarshallEVP, Research & InvestmentsOct 05 '26Sale57.104,126235,5950Oct 05 05:12 PM
Urist MarshallOfficerOct 05 '26Proposed Sale57.104,126235,595Oct 05 04:02 PM
Urist MarshallEVP, Research & InvestmentsSep 28 '26Sale57.884,126238,8134,126Sep 30 04:32 PM
Urist MarshallOfficerSep 28 '26Proposed Sale57.884,126238,813Sep 28 04:09 PM
Hite ChristopherEVP & Chairman, PartneringSep 22 '26Sale58.53100,0005,853,095270,401Sep 24 04:10 PM
SCH Investment Partners LLCOfficerSep 22 '26Proposed Sale58.47100,0005,846,972Sep 22 04:50 PM
Hite ChristopherEVP & Chairman, PartneringAug 18 '26Sale59.97100,0005,997,250370,401Aug 19 04:20 PM
SCH Investment Partners LLCOfficerAug 18 '26Proposed Sale60.12100,0006,012,000Aug 18 04:45 PM
Coyne Terrance P.EVP & CFOAug 13 '26Sale58.6811,002645,5510Aug 17 05:01 PM
Terrance CoyneOfficerAug 13 '26Proposed Sale58.5611,002644,277Aug 13 04:43 PM
Errol B. De SouzaFormer AffiliateAug 12 '26Proposed Sale57.79206,35211,925,082Aug 12 06:32 PM
Errol B. De SouzaFormer AffiliateAug 12 '26Proposed Sale57.79125,0007,223,750Aug 12 06:28 PM
Urist MarshallEVP, Research & InvestmentsJul 01 '26Sale55.889,099508,4540Jul 02 04:10 PM
Hite ChristopherEVP & Chairman, PartneringJun 30 '26Sale56.52100,0005,651,813459,399Jul 02 04:08 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VFLOVictoryShares Free Cash Flow ETFAUM: 12.50B
IWRiShares Russell Mid-Cap ETFAUM: 58.68B
VYMVanguard High Dividend Yield Indx ETFAUM: 83.15B
CGDGCapital Group Dividend Growers ETFAUM: 5.98B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
IWDiShares Russell 1000 Value Index FundAUM: 84.71B
MTUMiShares MSCI USA Momentum Factor ETFAUM: 16.69B
GSLCGoldman Sachs ActiveBeta U.S. Large Cap Equity ETFAUM: 14.88B
IWSiShares Russell Mid-Cap Value ETFAUM: 15.08B

News

latest 14 of 206
  • Royalty Pharma Raises Guidance A Third Time As Q3 Royalty Growth Slows And Pelacarsen Fails (Earnings Whispers)
  • Royalty Pharma: Q3 Earnings Snapshot (Associated Press)
  • Royalty Pharma reports third quarter 2026 results (GlobeNewswire)
  • Royalty Pharma Nears Record High As Third Straight Guidance Raise Becomes The Real Test (Earnings Whispers)
  • Royalty Pharma declares fourth quarter 2026 dividend (GlobeNewswire)
  • Loading…
  • Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 (GlobeNewswire)
  • Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program (GlobeNewswire)
  • Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Quartz)
  • Royalty Pharma to present at upcoming investor conferences (GlobeNewswire)
  • Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen (GlobeNewswire) -5.27%
  • MRK, RPRX Stocks Hit 52-Week Highs What Drove Todays Gains? (Stocktwits)
  • Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million (GlobeNewswire)
  • Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highlights: Daraxonrasib Poised to ... (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-041.2081.1811.208890884.846
2026Q22026-08-051.3211.2730.040773758.936
2026Q12026-05-061.2961.2140.674925881.694
2025Q42026-02-111.4661.2860.499874806.967
2025Q32025-11-051.1730.9940.665814717.387
2025Q22025-08-061.1411.0320.071680.76672.996
2025Q12025-05-080.7490.9530.545839705.344
2024Q42025-02-111.1511.0550.467742687.17
2024Q32024-11-060.9170.9281.214735696.927
2024Q22024-08-080.9620.9650.226608627.426
2024Q12024-05-090.9780.9870.011717665.575
2023Q42024-02-151.1491.0101.106682.22685.526
2023Q32023-11-080.7890.7700.160637.05631.745
2023Q22023-08-080.8450.8300.505543.15543.74
2023Q12023-05-091.6031.2740.7651,132902.026
2022Q42023-02-151.5591.472-1.0291,0641,0648

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY2.4432.4602.5971,7941,802
2021FY2.8192.8641.4942,1292,156
2022FY3.6823.6360.0982,7892,791
2023FY4.4794.2352.5342,9382,986
2024FY4.1284.0491.9122,8012,689
2025FY4.8304.6331.3673,2543,009
2026FY-5.393--3,540
2027FY-5.911--3,861
2028FY-6.592--4,201
2029FY-7.130--4,638
2030FY-7.870--5,083

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-04420960.74915986.97
2026Q4S2026-10-21310941.99915986.97
2026Q4S2026-10-20320941.32913986.97
2026Q4S2026-10-05330941.32913986.97
2026Q4S2026-09-07321935.39895.19986.97
2026Q4S2026-09-04330941.6913987.81
2026Q4S2026-08-07321935.67895.19987.81
2026Q4S2026-08-06311914.78895.19925.14
2026Q4S2026-08-05301908.11895.19925.14
2026Q4S2026-07-21301908.11895.19925.14
2026Q4S2026-07-20301908.05895925.14
2026Q4S2026-07-10302908.05895925.14
2026Q4S2026-05-12301924.07904943.08
2026Q4S2026-05-06311924.07904943.08

Estimate history

EPS, annual1.9932.276.4192.5971.4940.0982.5341.9121.7811.5369
Period201720182019202020212022202320242025TTM
EPS, quarterly1.2140.4670.5450.0710.6650.4990.6740.040.324
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1597.931794.8941814.2542122.3532289.4632237.2152354.5542263.5762378.1932616.82
Period201720182019202020212022202320242025TTM
Sales, quarterly564.69594568.247578.665609.291622630.576674.141690.103
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual607.035607.035365.899388.135432.963443.166446.692445.985428.669445.822
Period201720182019202020212022202320242025MRQ
Shares, quarterly446.038445.985425.59432.288429.027428.669443.628445.745445.822
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2,616.822,378.192,263.582,354.552,237.222,289.462,122.351,814.251,794.89
Cost of Goods Sold Incl. D&A4.883.85--5.6723.00---
Gross Profit2,611.942,374.34--2,231.552,266.47---
Selling, General and Administrative Excl. Other1,163.651,110.66238.67301.75404.41382.91208.00186.47454.51
Research and Development251.80452.002.0052.00177.11200.0826.2983.04392.61
Other Operating Expense-266.50-295.84732.46560.66904.24452.84295.89-1,019.32-57.33
Operating Income1,714.801,559.521,292.441,492.15922.891,430.711,595.402,623.181,364.45
Interest Expense372.00307.66225.51187.19187.96166.14156.54275.46290.15
Unusual Expense219.97-24.01-188.46-315.69559.4751.74-227.14-129.68-16.18
Net Income Before Taxes1,172.381,324.191,330.811,700.09230.061,241.201,701.952,461.421,517.86
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income1,172.381,324.191,330.811,700.09230.061,241.201,701.952,461.421,517.86
Net Income From Continuing Operations671.25770.95858.981,134.8342.83619.73975.042,348.531,377.73
Net Income671.25770.95858.981,134.8342.83619.73975.042,348.531,377.73
EPS (Recurring)1.701.751.692.170.991.582.176.172.25
EPS (Basic, Before Extraordinaries)1.541.791.922.540.101.492.606.422.27
EPS (Diluted)1.541.781.912.530.101.492.606.422.27
EBITDA1,719.681,563.371,292.441,492.15928.561,453.711,618.462,647.101,397.71
Non-Operating Income (Expense)49.0848.3375.4379.4454.6128.3735.95-15.98427.38
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense460.58290.892.342.362.173.105.70--
Price To Earnings Ratio45.1945.199.9870.1934.0626.3819.048.14-
Price To Sales Ratio12.429.176.707.197.747.228.85--
Gross Margin99.8199.84--99.7599.00---
Operating Margin65.5365.5857.1063.3741.2562.4975.17144.5976.02
Net Margin25.6532.4237.9548.201.9127.0745.94129.4576.76
Shares Outstanding445.82428.67445.99446.69443.17432.96388.13365.90607.04
Market Capitalization30,923.7230,923.7211,334.1412,610.3617,432.4317,016.1919,426.0119,185.36-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue690.10674.14630.58622.00609.29578.66568.25594.00
Cost of Goods Sold Incl. D&A1.221.291.171.201.28---
Gross Profit688.88672.85629.40620.80608.01---
Selling, General and Administrative Excl. Other216.00539.73198.11209.80168.72572.80161.2169.00
Research and Development63.1697.8539.7951.0050.50300.5050.501.00
Other Operating Expense-88.320.00-201.1923.0012.13-203.94-127.14164.00
Operating Income561.20133.12632.48388.00427.16209.80534.18361.00
Interest Expense90.4993.6293.7294.1779.5668.6765.2666.00
Unusual Expense216.75-34.2896.29-58.80-75.3459.9750.1639.45
Net Income Before Taxes266.6481.49468.26356.00444.2190.64433.43334.00
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income266.6481.49468.26356.00444.2190.64433.43334.00
Net Income From Continuing Operations144.6817.88294.69214.00288.2230.18238.35208.00
Net Income144.6817.88294.69214.00288.2230.18238.35208.00
EPS (Recurring)0.60-0.000.790.400.570.150.610.51
EPS (Basic, Before Extraordinaries)0.320.040.670.500.670.070.550.47
EPS (Diluted)0.320.040.670.500.670.070.550.47
EBITDA562.42134.41633.65389.20428.43209.80534.18361.00
Non-Operating Income (Expense)12.687.7125.792.9021.289.4814.6778.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense105.15107.36122.29125.790.000.000.520.53
Price To Earnings Ratio45.1929.3726.9422.1015.3614.6916.239.98
Price To Sales Ratio12.4212.3110.946.968.408.797.956.64
Gross Margin99.8299.8199.8199.8199.79---
Operating Margin81.3219.75100.3062.3870.1136.2694.0160.77
Net Margin20.962.6546.7334.4147.305.2141.9435.02
Shares Outstanding445.82445.75443.63428.67429.03432.29425.59445.99
Market Capitalization30,923.7224,854.3720,551.2616,508.8615,251.3015,182.0013,489.4111,334.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments637.50987.23495.311,736.472,188.922,061.94340.651,924.211,381.57
Short Term Receivables883.70810.73775.09727.92682.66626.36491.33660.450.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets6.894.193.8090.526.638.600.0923.890.00
Total Current Assets1,528.091,802.141,274.192,554.912,878.212,696.90832.072,608.552,947.72
Net Property, Plant & Equipment19.100.000.000.000.000.000.000.000.00
Total Investments and Advances880.281,259.881,012.48735.82909.59903.48678.41308.710.00
Intangible Assets17,133.1215,127.1614,088.6613,493.1113,723.9212,396.7510,893.788,452.888,789.64
Other Assets60.1933.536.5229.634.1423.1645.630.000.00
Total Assets19,620.7818,222.7216,381.8516,813.4717,515.8716,020.2912,449.9011,370.1511,373.53
Short Term Debt Incl. Current Port. of LT Debt380.00997.770.00997.510.000.00281.98281.44280.93
Accounts Payable19.4013.3715.167.915.6210.7811.184.480.00
Other Current Liabilities236.81242.47146.21161.37165.63297.1140.26294.26102.48
Total Current Liabilities636.211,253.62161.381,166.78171.25307.89333.42580.17383.41
Long Term Debt8,587.026,614.656,135.286,118.817,096.075,816.585,956.146,237.906,520.85
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities682.6112.080.902.500.000.0018.900.000.00
Total Liabilities9,905.847,880.356,297.567,288.097,267.326,124.476,308.466,818.076,904.27
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6,476.906,946.586,526.505,628.155,776.594,818.786,105.564,488.214,460.55
Total Shareholders Equity6,476.906,946.586,526.505,628.155,776.594,818.786,105.564,488.214,460.55
Accumulated Minority Interest3,238.043,395.783,557.793,897.224,471.955,077.0435.8863.870.00
Total Equity9,714.9410,342.3710,084.299,525.3710,248.559,895.826,141.444,552.084,460.55
Total Liabilities & Stockholders Equity19,620.7818,222.7216,381.8516,813.4717,515.8716,020.2912,449.9011,370.1511,364.81
Book Value Per Share15.1115.5814.6112.7013.3412.4216.697.397.35
Tangible Book Value Per Share-24.86-18.34-16.93-17.75-18.36-19.52-13.09-6.53-7.13
Full-Time Employees1009989756651---
Price to Book Ratio4.531.662.042.832.994.034.11--
Return on Assets4.074.966.840.253.706.8519.7212.1211.07
Return on Equity11.4912.7518.670.7511.7017.8544.3430.7927.17
Return on Invested Capital5.126.338.960.364.819.1719.4712.8411.02
Quick Ratio2.401.447.902.1916.818.762.504.507.69
Current Ratio2.401.447.902.1916.818.762.504.507.69

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income1,172.291,324.191,330.811,700.09230.061,241.201,701.952,461.421,517.86
Depreciation4.883.850.000.005.6723.0023.0623.9233.27
Other Funds (Non Cash)-1,702.24-2,070.67-1,574.98-1,875.20-631.65-1,545.6786.79-1,078.69-423.02
Funds from Operations-525.07-742.63-244.17-175.11-395.92-281.471,811.801,406.651,128.10
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3,520.053,337.603,036.793,206.792,539.902,299.53237.91260.58490.21
Cash from Operating Activities2,994.992,594.972,792.633,031.682,143.982,018.062,049.711,667.241,618.32
Capital Expenditures-1,716.07-1,697.73-2,523.70-2,115.52-1,762.86-2,191.50-2,182.25-1,721.29-269.59
Net Assets From Acquisitions0.00-74.420.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.005.925.1112.457.1944.2167.440.000.00
Purchase or Sale of Investments-93.61333.07-105.0913.29733.43339.30-592.16-136.01573.02
Purchase of Investments-181.50-233.43-223.46-12.54-812.11-1,437.01-1,795.44-660.56-176.98
Sale Or Maturity of Investments87.89566.50118.3625.831,545.541,776.311,203.28524.55750.00
Other Uses-66.44-280.26-75.00-14.440.00-18.600.00-258.840.00
Other Sources0.000.002.040.000.000.00-0.000.00
Cash from Investing Activities-1,876.12-1,713.41-2,696.65-2,104.22-1,022.23-1,826.59-2,706.97-2,116.14303.42
Cash Dividends Paid-408.87-378.25-376.46-358.33-333.32-285.18-397.84-739.28-814.36
Change in Capital Stock-261.62-1,227.38-229.65-304.760.000.001,908.740.000.00
Repurchase of Common Pref Stock-261.62-1,227.38-229.65-304.760.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.001,908.740.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.001,908.740.000.00
Issuance or Reduction of Debt, Net-385.29937.911,458.62-1,000.000.001,259.49633.92-294.00-294.00
Change in Long Term Debt-385.29937.911,458.62-1,000.000.001,259.49633.92-294.00-294.00
Issuance of Long Term Debt-1,230.291,937.911,458.620.000.001,259.4911,844.320.000.00
Reduction of Long Term Debt845.00-1,000.000.00-1,000.000.000.00-11,210.40-294.00-294.00
Net Financing Active Other Cash Flow-488.38-524.17-496.46-496.52-617.38-633.40-725.09-158.35-270.74
Other Financing Activities Uses-488.38-524.17-496.46-496.52-617.38-633.40-725.09-158.35-270.74
Cash from Financing Activities-1,544.15-1,191.89356.04-2,161.20-952.05340.901,419.73-1,191.63-1,379.10
Net Change in Cash-425.29-310.33452.02-1,233.74169.70532.37762.48-1,640.53542.64
Free Cash Flow2,994.992,594.972,792.633,031.682,143.982,018.062,049.71--
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow12.579.846.276.339.569.5411.38--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments544.86836.99608.29637.50955.04645.11
Short Term Receivables972.81920.93807.36883.70888.97870.68
Inventories0.000.000.000.000.000.00
Other Current Assets7.906.6610.166.895.524.45
Total Current Assets1,525.571,764.571,425.811,528.091,849.541,520.24
Net Property, Plant & Equipment0.000.000.0019.100.000.00
Total Investments and Advances808.61875.99845.77880.28722.85658.34
Intangible Assets17,065.4817,116.2517,466.9917,133.1216,688.3116,058.92
Other Assets61.5762.9676.8560.1986.5885.49
Total Assets19,461.2219,819.7719,815.4219,620.7819,347.2818,323.00
Short Term Debt Incl. Current Port. of LT Debt996.97380.00380.00380.00380.00999.44
Accounts Payable31.4235.5725.4819.4041.4120.21
Other Current Liabilities150.61215.36130.20236.81109.39186.88
Total Current Liabilities1,179.00630.93535.68636.21530.801,206.53
Long Term Debt7,590.528,581.898,576.448,587.028,582.647,020.76
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities896.43821.24766.46682.61612.98592.77
Total Liabilities9,665.9510,034.069,878.589,905.849,726.428,820.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6,836.926,832.746,888.556,476.906,414.356,347.91
Total Shareholders Equity6,836.926,832.746,888.556,476.906,414.356,347.91
Accumulated Minority Interest2,958.352,952.973,048.293,238.043,206.513,155.03
Total Equity9,795.279,785.719,936.839,714.949,620.869,502.94
Total Liabilities & Stockholders Equity19,461.2219,819.7719,815.4219,620.7819,347.2818,323.00
Book Value Per Share15.3415.3315.5315.1114.9514.68
Tangible Book Value Per Share-22.94-23.07-23.85-24.86-23.95-22.46
Full-Time Employees---100--
Price to Book Ratio4.533.613.172.582.402.29
Return on Assets3.464.274.424.074.095.67
Return on Equity10.1312.3612.1811.4811.5115.92
Return on Invested Capital1.000.121.911.421.920.23
Quick Ratio1.292.802.662.403.481.26
Current Ratio1.292.802.662.403.481.26

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income266.6481.48468.26355.91444.2190.64
Depreciation1.221.291.171.201.28-
Other Funds (Non Cash)-399.49-269.08-544.07-489.61-573.45-441.26
Funds from Operations-131.63-186.30-74.64-132.50-127.96-349.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital818.69901.54835.18964.64831.48776.22
Cash from Operating Activities687.06715.25760.54832.14703.52426.97
Capital Expenditures-279.00-251.02-452.37-733.68-961.87-1.11
Net Assets From Acquisitions0.000.000.000.00-0.23-74.19
Sale of Fixed Assets and Businesses0.000.000.000.00-0.204.82
Purchase or Sale of Investments5.7634.83-17.80-116.402.88-72.12
Purchase of Investments0.00-5.00-22.50-154.000.00-75.00
Sale Or Maturity of Investments5.7639.834.7037.602.882.88
Other Uses-13.41-0.32-50.00-2.710.00-227.55
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-286.65-216.51-520.17-852.79-959.42-370.15
Cash Dividends Paid-105.12-104.92-104.49-94.34-95.31-93.24
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-86.34-44.64-50.10-80.54-146.49-291.57
Repurchase of Common Pref Stock-86.34-44.64-50.10-80.54-146.49-291.57
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-382.270.000.00-3.02940.930.00
Change in Long Term Debt-382.270.000.00-3.02940.930.00
Issuance of Long Term Debt47.730.000.00-1,278.023,215.930.00
Reduction of Long Term Debt-430.000.000.001,275.00-2,275.000.00
Net Financing Active Other Cash Flow-127.48-121.13-118.08-121.69-136.19-127.83
Other Financing Activities Uses-127.48-121.13-118.08-121.69-136.19-127.83
Cash from Financing Activities-698.74-273.15-272.67-299.60562.94-512.64
Net Change in Cash-298.33225.59-32.30-320.25307.04-455.81
Free Cash Flow687.06715.25760.54832.14703.52426.97
Price to Free Cash Flow12.5711.9511.447.479.269.45

Revenue breakdown

Financial Royalty Assets2024: 2.15B 2025: 2.26B
Royalty Income, Other2024: 114.15M 2025: 117.04M
United States2024: 2.26B 2025: 2.38B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.13%13.1M417.1M3.06M
2026-10-153.07%12.8M418.4M2.96M
2026-09-303.09%12.9M417.2M2.91M
2026-09-152.79%11.6M417.1M3.12M
2026-08-312.86%11.9M416.9M3.14M
2026-08-142.78%11.6M416.9M3.52M
2026-07-312.56%10.7M416.9M3.63M
2026-07-152.92%12.1M415.0M3.73M
2026-06-303.00%12.4M415.0M3.73M
2026-06-152.69%11.1M414.6M3.61M
2026-05-292.81%11.6M412.0M3.56M
2026-05-153.08%12.7M411.9M3.32M
2026-04-303.35%13.8M412.0M3.41M
2026-04-153.02%12.0M397.1M3.51M
2026-03-312.90%11.5M396.9M3.70M
2026-03-132.92%11.6M396.9M3.68M
2026-02-273.06%12.2M396.9M3.90M
2026-02-133.39%13.4M396.9M4.03M
2026-01-306.81%26.5M388.9M4.20M
2026-01-158.18%27.5M336.5M3.93M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call35.0031.8036.500.004.1690.000.000.964-0.1300.009
call37.5029.1034.000.003.8300.000.000.960-0.1280.009
call40.0026.6031.500.003.4910.000.000.956-0.1260.010
call42.5024.1029.000.003.2160.000.000.952-0.1240.011
call45.0021.9026.500.002.8940.000.000.947-0.1210.012
call47.5019.1024.000.002.6650.000.000.941-0.1180.013
call50.0016.7021.500.002.4080.000.000.934-0.1140.014
call52.5014.4019.006.272.1601.000.000.926-0.1100.015
call55.0012.5016.405.001.7572.000.000.918-0.1070.017
call57.5010.0014.009.241.6583.000.000.904-0.1010.019
call60.007.5011.507.701.3505.000.000.889-0.0950.021
call62.504.509.305.201.2094.000.000.857-0.0890.025
call65.003.905.403.820.6511990.000.800-0.0860.031
call67.500.004.001.700.63523.000.000.648-0.1430.041
call70.000.001.550.650.44414.000.000.478-0.1690.043
call72.500.004.000.000.6510.000.000.357-0.1570.041
call75.000.001.200.600.6862.000.000.281-0.1430.038
call80.000.004.900.100.9923.000.000.209-0.1730.032
call85.000.001.800.001.2690.000.000.176-0.1980.028
put35.000.004.900.002.7400.000.00-0.035-0.1290.009
put37.500.004.900.002.5050.000.00-0.039-0.1270.009
put40.000.004.900.002.2810.000.00-0.043-0.1250.010
put42.500.004.900.002.0500.000.00-0.048-0.1220.011
put45.000.004.900.001.8660.000.00-0.052-0.1190.012
put47.500.004.900.001.6780.000.00-0.057-0.1160.013
put50.000.000.850.001.4720.000.00-0.065-0.1120.014
put52.500.004.900.251.31869.000.00-0.071-0.1080.015
put55.000.004.900.651.1246.000.00-0.083-0.1030.017
put57.500.000.900.050.9555.001.00-0.096-0.0970.019
put60.000.002.450.500.7757.000.00-0.111-0.0840.022
put62.500.004.900.000.6470.000.00-0.133-0.0830.024
put65.000.000.500.000.4500.000.00-0.197-0.0800.030
put67.500.001.701.130.5723.000.00-0.381-0.1410.042
put70.000.004.900.001.0280.000.00-0.519-0.1650.043
put72.501.155.900.000.8610.000.00-0.641-0.1550.041
put75.003.508.300.001.0510.000.00-0.729-0.1470.036
put80.008.5013.300.001.3720.000.00-0.794-0.1700.031
put85.0013.5018.400.001.6840.000.00-0.824-0.1910.028

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-17SCHEDULE 13D/ASEC
2026-08-1413F-NTFurther understand that each of 13F-HR, 13F-NT, and amendments thereto are mandatory electronic filings (hardship exemption exists to submit in paper; never used to the knowledge of IM staff);2026-06-30SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000235.59K1
2026-09006.09M2
2026-08006.64M2
2026-0700508.45K1
2026-060016.01M4
2026-05005.09M4
2026-04003.41M2
2026-03003.21M2
2026-020011.94M4
2026-01009.41M7
2025-120019.67M12
2025-110010.61M4

Institutional holders

Manager% owned
MORGAN STANLEY9.69%
Capital International Investors7.96%
BlackRock, Inc.6.28%
FMR LLC4.35%
STATE STREET CORP2.78%
PRICE T ROWE ASSOCIATES INC /MD/2.53%
Swedbank AB2.30%
Capital World Investors2.15%
BAILLIE GIFFORD & CO2.06%
GEODE CAPITAL MANAGEMENT, LLC1.92%

Funds

Fund% owned
DFA Investment Grade Portfolio16.30%
Baird Aggregate Bond Fund9.26%
Baird Core Plus Bond Fund6.68%
LORD ABBETT BOND DEBENTURE FUND INC5.20%
VANGUARD INTERMEDIATE-TERM CORPORATE BOND INDEX FUND4.60%
New Perspective Fund4.43%
Transamerica Short-Term Bond4.17%
Bond Fund3.52%
Lord Abbett Ultra Short Bond Fund3.43%
DoubleLine Low Duration Bond Fund3.08%

OakChart. RPRX. Cached 15 minutes.